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EFFICACY AND SAFETY OF BORTEZOMIB WITH DEXAMETHASONE 
REGIMEN IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA 
PATIENTS WITH CO-MORBIDITIES 
SAEM LEE 
ABSTRACT 
Bortezomib-based induction therapies have shown to increase complete 
response rates and are used as an upfront therapy for newly diagnosed multiple 
myeloma patients. The standard treatment uses twice a week bortezomib at 1.3 
mg/m2 with dexamethasone PO on the day of and day after bortezomib, 
however, peripheral neuropathy is often a dose-limiting factor. For elderly 
patients with multiple co-morbidities and polypharmacy, we propose an alternate 
schedule of once a week bortezomib IV at 1.6 mg/m2 with dexamethasone PO on 
the day of and day after bortezomib. In this phase II, open-labeled, multi-site 
study, we hypothesize that patients receiving weekly bortezomib will have 
comparable efficacy as the standard twice a week schedule with increased 
convenience and lower toxicity profile, especially related to peripheral 
neuropathy. Methods: 50 patients with newly diagnosed symptomatic multiple 
myeloma who were ineligible for transplant or postponed transplant were enrolled 
from 12 Veterans Affairs hospitals. One cycle consisted of once a week 1.6 
mg/m2 bortezomib IV (days 1, 8, 15, 22) plus dexamethasone PO on the day of 
and after bortezomib (days 1, 2, 8, 9, 15, 16, 22, 23) for 4 weeks, with the 5th 
week off of treatment. Responding patients could receive up to 6 cycles. 
  v
Results: The median age of patients was 71 ±1.46 years (range: 50-89) with β-2 
microglobulin of 5.80 ± 0.46 mg/L and c-reactive protein of 10.61 ± 5.54 mg/L. 
Patients also had multiple co-morbidities including cardiovascular disease (76%) 
renal insufficiency (54%) and pulmonary problems (36%) and were receiving a 
median of 13 concurrent medications at baseline. Of the fifty patients, 43 patients 
were evaluable for response. Seven patients received <1 cycle or died before 
response could be evaluated. An objective response rate of 79% was observed 
in 43 evaluable patients with 14% achieving nCR/CR, and at least VGPR in 44% 
of patients. The median progression-free survival was 9.6 months and overall 
survival was 46.5 months. The most common toxicity of all grades was 
thrombocytopenia (42%), lymphopenia (46%), asthenia (48%), and constipation 
(38%). Peripheral neuropathy occurred in 24% with grade 3 neuropathy occurring 
only in 6% of patients. In conclusion, a weekly bortezomib plus dexamethasone 
regimen is efficacious and safe, with lower neurotoxicity in elderly patients with 
newly diagnosed multiple myeloma complicated by extensive co-morbidities and 
polypharmacy.  
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INTRODUCTION 
Multiple Myeloma  
Multiple myeloma is a hematologic malignancy characterized by 
uncontrolled proliferation of a clone of plasma cells in the bone marrow that  
accumulates in the blood and kidney, leading to disease related end-organ 
damage (Palumbo & Anderson, 2011). It is the second leading blood cancer with 
a strong, global significance. In 2013, the projected incidence of multiple 
myeloma in the United States alone is estimated at 22,350 cases and 
approximately 10,710 deaths (Siegel, Naishadham, & Jemal, 2013).  Multiple 
myeloma can alter the bone marrow microenvironment, resulting in anemia, bone 
resorption with subsequent hypercalcemia, and impaired immunity. Bone lesions 
caused by the imbalance of bone remodeling mechanism increases the risk of 
fractures (Palumbo & Anderson, 2011).  The malignant plasma cells secrete 
monoclonal proteins that can be detected in serum and in urine and cause renal 
failure. Although a direct causal relationship has yet to be elucidated, some 
known risk factors include the diagnosis of monoclonal gammopathy of 
undetermined significance (MGUS). More men than women are affected by 
multiple myeloma and it is also more common among African Americans (Shirley, 
Sayeed, Barnes, Finlayson, & Ali, 2013; Waxman et al., 2010). The median age 
at diagnosis is 69 years (“SEER Stat Fact Sheets: Myeloma,” n.d.), with a 
survival rate of  29 to 62 months, depending on several prognostic 
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markers(Greipp et al., 2005). Although it is currently an incurable cancer, survival 
rates have greatly improved especially in the past few years, with the advent of 
novel drugs, such as bortezomib, and more effective supportive therapies 
(Kumar et al., 2008). 
The evolution of multiple myeloma begins with MGUS which then 
progresses to smoldering myeloma, and eventually fully manifests as 
symptomatic multiple myeloma which requires intervention. MGUS is 
characterized by < 3g/dL of monoclonal protein in serum, < 10% malignant 
plasma cells in the bone marrow, and no evidence of end-organ damage. End-
organ damage further differentiates symptomatic from asymptomatic 
(smoldering) multiple myeloma, and the three different stages are defined in 
Table 1 (Dimopoulos et al., 2011). Although symptomatic myeloma patients can 
be traced back to having MGUS at some point, not all MGUS patients progress 
to symptomatic multiple myeloma. The overall progression rate of MGUS to 
smoldering myeloma is estimated at 1% per year (Kyle et al., 2002) and the 
cumulative probability of progression from smoldering to symptomatic myeloma 
is estimated as 73% in 15 years (Kyle et al., 2007). Once myeloma becomes 
symptomatic, typical clinical presentations include bone pain associated with lytic 
bone lesions, hypercalcemia, renal dysfunction, proteinuria, recurrent infection, 
fatigue, and anemia (Palumbo & Anderson, 2011).   
  
3 
 
Clinical Investigation 
The diagnostic tests recommended by the International Myeloma 
Workshop consensus panel include a measurement of protein electrophoresis, 
free light chains, and proteinuria, a skeletal survey, and evaluation of the bone 
marrow.  A serum protein electrophoresis and immunofixation identifies and 
quantifies the monoclonal protein, as well as identifies the involved heavy and 
light chain (Dimopoulos et al., 2011). A serum-free light chain (FLC) quantitation 
is important because it can detect myeloma that does not secrete 
immunoglobulin heavy chain, or detect small amounts of monoclonal protein 
(Dimopoulos et al., 2011). A 24-hour urine measure of proteinuria and urine 
immunofixation identify immunoglobulins and help establish patients at risk for 
renal failure (Dimopoulos et al., 2011).  A bone marrow biopsy and analysis of 
aspirate smear is required to measure the percentage of abnormal plasma cells 
present, which can help determine if the patient meets the criteria for MGUS or 
smoldering/symptomatic multiple myeloma, but also provide information on 
intrinsic properties of the myeloma, such as its genetics. (Dimopoulos et al., 
2011). Lytic lesions can be detected by a skeletal survey and can identify areas 
which have increased risk of fracture (Dimopoulos et al., 2011). 
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Table 1. Classifications of plasma cell disorders. Monoclonal gammopathy of undetermined significance 
(MGUS) progresses to smoldering multiple myeloma which advances to symptomatic multiple characterized by 
end-organ damage (Table taken from Dimopoulos et al., 2011). 
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Treatment Options 
Treatment for newly diagnosed multiple myeloma (NDMM) can be divided 
into two broad approaches depending on whether a patient is eligible for 
autologous stem cell transplantation (Fig.1) (Palumbo & Anderson, 2011). For 
newly diagnosed younger and fitter patients (age < 65 years) with adequate liver, 
cardiac, renal, and pulmonary function, autologous stem cell transplant (ASCT) is 
considered the standard treatment (Jasielec & Jakubowiak, 2013). Prior to 
transplant, patients typically undergo induction therapy. The overall goal of 
induction therapy is to reduce tumor burden, improve end-organ damage, and 
achieve the best response prior to a transplant, resulting in more frequent and 
sustained post-transplant responses (Jasielec & Jakubowiak, 2013; Moreau, 
Attal, et al., 2011; Niesvizky et al., 2008). Some alkylating agents, such as 
melphalan, are avoided as they are toxic to hematopoietic stem cells and can 
reduce mobilization of stem cells for transplant (Kyle & Rajkumar, 2004). Three 
drug combination of vincristine, doxorubicin, and dexamethasone or thalidomide 
plus dexamethasone as induction therapies have shown similar response rates 
pre-transplant (Kyle & Rajkumar, 2004).  New strategies have incorporated novel 
agents, such as proteasome inhibitors and immunomodulators, resulting in 
improved response rates. 
Multiple myeloma disproportionately affects the elderly and as a result, 
many of those affected are not candidates for transplantation. Therefore, 
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establishing an effective and standardized treatment that is not inferior to ASCT 
is a very important goal which will benefit many patients.  Novel agents are 
making it possible for an increasing number of patients to achieve complete 
response (CR) without ASCT. A retrospective study of three multi-center trials 
has demonstrated that a significant number of older patients (age > 75 years) 
could attain high rates of CR, which correlated longer progression-free survival 
(PFS) and overall survival (OS). The 3-year progression-free survival of 25% and 
3-year overall survival of 54% in older patients  were similar to younger patients 
who had survival rates of 29% and 65%, respectively (Gay et al., 2011). Although 
transplant has long been considered the closest to a curative treatment, some 
have suggested that we may be getting closer to managing multiple myeloma on 
a long-term basis through a combination maintenance therapy using novel drugs 
(Palumbo, Attal, & Roussel, 2011).  
 Treatment options for patients who are ineligible for transplant can be 
subdivided into two-drug or three-drug combinations (Palumbo & Anderson, 
2011). The three-drug combination mainly uses melphalan and prednisone with 
the third drug a choice among thalidomide, bortezomib, or lenalidomide 
depending on a patient’s comorbidities, tempo of the disease, and organs at risk. 
Randomized clinical trials have shown that a two-drug combination of 
dexamethasone with either bortezomib or lenalidomide can be used as an 
alternative to the three-drug combination with good, overall response and 
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progression-free survival (Palumbo & Anderson, 2011). These treatments are 
summarized in Figure 1.
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Figure 1. Schematic overview of treatment options for newly diagnosed multiple myeloma. Although there is 
no consensus on a standardized treatment option, most treatments can be largely divided into two options 
depending on whether or not patients are eligible for autologous stem cell transplant (Figure taken from Palumbo & 
Anderson, 2011).
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Bortezomib use in Newly Diagnosed Multiple Myeloma 
Bortezomib is a reversible 26S proteasome inhibitor developed by 
Millennium Pharmaceuticals Incorporated which was approved by the Food and 
Drug Administration (FDA) in 2008 for previously untreated multiple myeloma 
(Research, n.d.). Bortezomib has antimyeloma activity by increasing the 
susceptibility of abnormal myeloma cells to apoptosis. A nuclear factor (NF-κB) 
regulates the transcription of genes associated with cell proliferation and cell 
survival. Normally, NF-κB is inactive and present in the cytosol bound to an 
inhibitory protein, Inhibitor of NF-κB (IκB). Once the proteasome degrades IκB, 
the NF-kB is now free to enter the nucleus to act as a transcription factor. 
Bortezomib binds to the proteasome to increase the level of IκB to indirectly 
target this NF-κB, which is highly active in multiple myeloma (Kyle & Rajkumar, 
2004). This has a cumulative effect of down-regulating adhesion molecule 
expression and angiogenic factors while also decreasing growth and survival of 
malignant myeloma cells in the bone marrow microenvironment (Kyle & 
Rajkumar, 2004).  
The efficacy of twice a week intravenous (IV) bortezomib at 1.3 mg/m2 has 
been demonstrated in relapsed multiple myeloma patients, as well as NDMM 
patients (Richardson et al., 2003; Jagannath et al., 2005). Bortezomib primarily 
undergoes oxidative metabolism in the liver and a single injection of 1.3 mg/m2 
has an estimated elimination half-life of 76 to 108 hours (“Velcade (Bortezomib) 
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Drug Information,” n.d.-a). In a large randomized phase 3 APEX (Assessment of 
Proteasome Inhibition for Extending Remissions) trial, high-dose dexamethasone 
was compared to a bi-weekly bortezomib regimen for relapsed multiple myeloma 
patients. The objective response rate (ORR) in the bortezomib arm was 38% 
while only 18% of patients achieved an ORR (Richardson et al., 2005). The 
complete response rate (CR) or near complete response rate (nCR) was higher 
in the bortezomib group than the comparator group (13% versus 2%), and the 
median time to progression was longer by 2.73 months and 1-year survival rates 
were  higher in the bortezomib group (80% versus 66%). The most common 
adverse events were diarrhea (57%), nausea (57%), and fatigue (42%), whereas 
thrombocytopenia (35%) was the most common hematologic adverse event. Of 
note, peripheral neuropathy occurred in 36% of patients with grade 3 occurring in 
7% and grade 4 in 1%. Another large phase 3 VISTA (Velcade as Initial Standard 
Therapy in Multiple Myeloma trial) comparing melphalan-prednisone with 
melphalan-prednisone-bortezomib also demonstrated that bortezomib improves 
efficacy in previously untreated multiple myeloma patients (San Miguel et al., 
2008). Objective response rates in this study were twice as higher in the 
bortezomib group (71%) than the comparator group (35%). The bortezomib 
group also had significantly higher rates of CR (30%) than the comparison group 
(4%) and the bortezomib group has sustained CR by 11.2 months longer than 
the comparison group. Similar to the APEX trial, the bortezomib group had a 
longer median time to progression and duration of response by 7.9 months and 
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6.8 months, respectively. Peripheral neuropathy of all grades occurred in 44% of 
patients, of which 13% had grade 3 and 1% had grade 4 neuropathy. 
Thrombocytopenia (52%) was the most common hematologic adverse event and 
the most common non-hematologic adverse events were nausea (48%) and 
diarrhea (46%).   
Abnormal kidney function can commonly complicated newly diagnosed 
multiple myeloma. Some novel agents, such as lenalidomide, are eliminated by 
the kidneys and should be used with caution in renal failure.  However, 
bortezomib is not renally excreted and can be safely given to patients with renal 
dysfunction. In fact, patients with severe renal impairment or on dialysis can be 
safely treated with bortezomib-based regimens. (Chanan-Khan et al., 2007; Li et 
al., 2009)  A retrospective analysis of the Italian Myeloma Network GIMEMA 
study showed reversal of renal impairment in approximately 40% of 117 patients 
treated with bortezomib, which was more evident in untreated multiple myeloma 
patients (Morabito et al., 2010). These studies demonstrate the safety of 
bortezomib use in patients with severe renal impairment, and it also supports the 
use of bortezomib to improve renal function of patients with end-organ damage 
caused by multiple myeloma. 
Common hematologic side effects of bortezomib include 
thrombocytopenia, neutropenia, anemia, leukopenia, and lymphopenia and non-
hematologic adverse reactions include gastrointestinal disorders (diarrhea, 
nausea, constipation, vomiting), fatigue, and peripheral neuropathy (“Velcade 
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(Bortezomib) Drug Information,” n.d.-b). Importantly, drug-induced peripheral 
neuropathy is of particular concern in bortezomib-based treatments and is often a 
dose-limiting factor in the standard bi-weekly regimen. Patients in a previous 
study have experienced peripheral neuropathy rates of 32.2%, of which 9.2% 
were grade 3-4 (J.-L. Harousseau et al., 2010). Post-hoc analysis and 
retrospective studies have shown that dose-modified bortezomib regimens have 
similar efficacies as the twice a week bortezomib regimen but with generally 
lower adverse events including lower rates of overall incidences of peripheral 
neuropathy (27% - 31%) (Bringhen et al., 2010; Moore et al., 2013), when 
compared to the bi-weekly bortezomib regimen group (46%) (Bringhen et al., 
2010).  
Aging is associated with progressive organ dysfunction and changes in 
metabolism, which contributes to drug metabolism and elimination. This can 
translate into a higher incidence and frequency of drug toxicity in elderly patients, 
when compared to younger patients. A large, multi-institutional cross-sectional 
analysis has shown that the elderly population with cancer has numerous and 
wide ranging comorbidities (Table 2) (Repetto et al., 2002), and concerns for 
potential drug interactions arising from polypharmacy. Frailty, disability, co-
morbidity, and potential drug interactions are additional factors which further 
complicate the treatment and management of multiple myeloma (Palumbo, 
Bringhen, et al., 2011) and thus investigation of the safety of bortezomib in 
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elderly patients is important, especially since myeloma commonly affects older 
individuals. 
A higher dose of 1.6 mg/m2 bortezomib IV weekly was proposed based on 
promising results from two other studies. A Phase I trial of single agent 
bortezomib in multiple myeloma showed that a weekly 1.6 mg/m2 was well-
tolerated and demonstrated anti-tumor activity (Papandreou et al., 2004). The 
most common toxicities were diarrhea, constipation, vomiting, fatigue, and 
hypotension; all of which were mild grade 2 in severity (Papandreou et al., 2004). 
More importantly, the incidence of peripheral neuropathy was low at 8%, 
occurring mostly in the first two cycles of treatment and in patients who were on 
other neurotoxic regimens prior to the study (Papandreou et al., 2004). Similarly, 
a Phase II study investigating a twice a week 1.5 mg/m2 bortezomib as a single 
agent in indolent and mantle cell non-Hodgkin’s lymphoma patients showed that 
a higher dose was well tolerated in approximately half (46%) of the patients 
without requiring dose modifications (O’Connor et al., 2005). The most common 
toxicities present in these patients included grade 3 lymphopenia (14 of 26 
patients) and grade 3 thrombocytopenia (7 of 26 patients), which quickly resolved 
to baseline during the 5th week break from treatment of each cycle (O’Connor et 
al., 2005). This study utilized a similar regimen as our proposed regimen of four 
weeks of treatment with a break in week five, consisting of one cycle. These 
studies provides further support for our hypothesis that a once a week 1.6 mg/m2 
bortezomib dose will be well tolerated, especially with a lower incidence of 
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peripheral neuropathy when compared to the standard 1.3 mg/m2  dosage more 
commonly used in induction therapy. We are also proposing a combination 
therapy with the addition of dexamethasone to bortezomib based on previous 
studies which have shown to have a synergistic role in increasing the response 
rate (Jagannath et al., 2005; Richardson et al., 2003).  
To our knowledge, this is the first prospective study investigating the 
safety and efficacy of a weekly 1.6 mg/m2 IV administration of bortezomib with a 
high dose oral (PO) dexamethasone on the day of and day after bortezomib in 
newly diagnosed elderly multiple myeloma patients with multiple co-morbidities 
and polypharmacy. 
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Table 2. Co-morbidities most frequently associated with elderly cancer patients.  Arthrosis-arthritis, 
hypertension, digestive disease, heart disease, and vascular disease ranked among the highest co-morbidities in 
cancer patients of age ≥ 65 years (Table taken from Repetto et al., 2002) 
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SPECIFIC AIMS/OJBECTIVES 
We propose the need for an alternative dosing schedule of bortezomib plus 
dexamethasone for elderly NDMM patients with multiple co-morbidities. We 
propose once a week 1.6 mg/m2 bortezomib IV with dexamethasone PO on the 
day of and day after bortezomib. To determine the efficacy and safety of this 
weekly regimen, the following aims will be addressed: 
Aim 1. Evaluate the objective response rate of NDMM patients on weekly 
bortezomib plus dexamethasone regimen using the criteria reported by SWOG 
(Kraut et al., 1998) and Bladé et al (Bladé et al., 1998) 
Aim 2. Evaluate the safety and toxicity of weekly bortezomib plus 
dexamethasone regimen in NDMM patients using the National Cancer Institute 
Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 
(“Microsoft Word - CTCAEv3_PubDate_2006-08-09.doc - ctcaev3.pdf,” n.d.). 
Aim 3. Evaluate the duration of response and time to progression after a weekly 
regimen of bortezomib plus dexamethasone for NDMM patients. 
We hypothesize that a modified weekly regimen of bortezomib with 
dexamethasone has a similar efficacy, when compared to the standard bi-weekly 
regimen. We also believe that patients on a weekly regimen with bortezomib plus 
dexamethasone will have an improved toxicity profile, especially relating to 
bortezomib-induced peripheral neuropathies. The results of this study should 
help guide physicians in choosing an effective and safer dosing induction 
regimen in an elderly population with multiple co-morbidities with polypharmacy. 
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METHODS 
Eligibility 
Over four years (from 2007 to 2011), 50 subjects with newly diagnosed 
multiple myeloma (who received no prior treatment) were recruited from 12 
participating Veteran Affairs (VA) hospitals (Appendix 1). Patients who had 
corticosteroid treatment for hypercalcemia or bisphosphonates, steroid 
equivalent to > 10 mg of prednisone daily for non-myeloma treatment were not 
excluded from the protocol. Although local spot radiotherapy to ≤ 3 vertebrae 
prior to study initiation were acceptable, a four-week washout period was 
required. Additionally, patients who required concurrent radiotherapy were 
considered ineligible until the completion of radiotherapy.  All patients were at 
least 18 years old with measurable disease, detected by either a monoclonal 
immunoglobulin spike on serum or urine electrophoresis, or by serum free light 
chain. Patients enrolled in the study were either ineligible for transplant or may 
have declined or postponed transplant as a treatment option. Other eligibility 
requirements included a baseline platelet count of ≥ 50 x 109/L, hemoglobin of ≥ 
8.0 g/dL, an absolute neutrophil count of ≥ 1.0 x 109/L, adequate liver function 
tests (Aspartate Transaminase and Alanine Aminotransferase  ≤ 3 times the 
upper limit of normal, total bilirubin ≤ 2 times the upper normal limit), and a 
Karnosky performance status (KPS) of ≥ 50. Patients were ineligible if they had 
known active HIV, hepatitis B or C infection, impaired kidney function requiring 
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dialysis or hemodialysis, plasma cell leukemia, POEMS (Polyneurophaty, 
Organomegaly, Endocrinopathy Monoclonal protein, Skin changes) syndrome, 
significant and/or persistent cardiac problems. Patients who experienced ≥ grade 
2 peripheral neuropathy within 14 days prior to enrollment were also excluded 
from the study. All male subjects agreed to use an acceptable method for 
contraception for the duration of the study and women with child-bearing 
potential were instructed to practice adequate form of contraception as judged by 
the investigator. A detailed eligibility criteria is presented in Appendix 2. The 
study was approved by the institutional review board at the coordinating center, 
VA Boston Healthcare System, as well as by each of the participating subsites’ 
institutional review boards. The study was conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice. All patients were provided 
written informed consents, and the study is registered in the ClinicalTrials.gov 
(NCT 01090921). 
 
Treatment 
The study was a Phase II, open-labeled, single-arm trial. Subjects 
received bortezomib at a dose of 1.6 mg/m2 intravenously in combination with 40 
mg of dexamethasone PO.   One cycle consisted of once weekly bortezomib (on 
days 1, 8, 15, 22) for four weeks, followed by a one week break.  
Dexamethasone was administered on the day of and day after administration of 
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bortezomib (on days 1, 2, 8, 9, 15, 16, 22, 23).  Patients who achieved at least 
minimal response (MR) could receive up to a maximum of six cycles on the 
protocol. Patients with bortezomib-related toxicity or neuropathic pain/peripheral 
sensory neuropathy could have dose modifications if they developed Grade 2 
neuropathy or Grade 1 neuropathy from pain (Appendix 3). In subjects unable to 
tolerate the high dose dexamethasone, a step-wise the dose reduction to 20 mg 
was permitted; if toxicity continued, the dexamethasone could be held.  Subjects 
were evaluated for response using the criteria previously reported (Bladé et al., 
1998; Kraut et al., 1998; Rajkumar et al., 2011) every two cycles. Subjects with at 
least stable disease by end of cycle two were eligible to continue on the protocol. 
Subjects who did not respond to treatment by end of the fourth cycle were taken 
off the study. Subjects who continued to have sustained response at the end of 
cycle six were followed to measure the duration of response until the beginning 
of a new treatment regimen or reported death (Fig. 2). 
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Figure 2. Flow chart of study schema.  Subjects who respond with minimal 
response (MR) or better can receive up to a maximum of six cycles of treatment. 
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Assessments 
Multiple myeloma laboratory evaluation performed during the study 
included serum protein electrophoresis (SPEP), serum immunofixation 
electrophoresis (SIFE), quantitative immunoglobulin panel, serum free light 
chains, and 24-hour urine protein electrophoresis and immunofixation 
(UPEP/IFE) at baseline. In addition, complete blood count (CBC) with 5-part 
differential, electrolytes, calcium, liver profile, β-2 microglobulin, and c-reactive 
protein (CRP) were also performed at screening. Patients also had a physical 
examination, electrocardiogram, chest x-ray, skeletal survey, and bone marrow 
biopsy performed at baseline. Standard multiple laboratory tests, CBC, calcium, 
liver profile, and physical exam were completed for each patient at the start of 
each cycle. Additionally, patients had laboratory tests for CBC, and calcium and 
electrolytes on days 8, 15, and 22 of each cycle. Subjects who achieved a near 
complete response (nCR) by the end of cycle 6 had a bone marrow biopsy and 
skeletal survey to confirm CR, including all laboratory tests performed at 
screening (Appendix 4). All subjects who had sustained responses of at least MR 
were followed every two weeks to assess time to next treatment (TTNT), PFS, 
OS. Severities of adverse events were graded based on the National Cancer 
Institute CTCAE version 3 (“Microsoft Word - CTCAEv3_PubDate_2006-08-
09.doc - ctcaev3.pdf,” n.d.).  Adverse events were categorized into five groups in 
relation to the study drug which ranged from the following: definitely not related, 
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probably not related, possibly related, probably related, and definitely related. 
Adverse events considered less than probably related were excluded. 
Response to treatment was assessed based on the criteria as reported by 
SWOG (Kraut et al., 1998) and Bladé et al (Bladé et al., 1998). Briefly, a 
complete response is defined as having a negative serum and urine 
immunofixation with < 5% abnormal plasma cells as confirmed by bone marrow 
biopsy and no increase in the size or number of lytic bone lesions on 
radiographic studies with a disappearance of soft tissue plasmacytomas if 
present at baseline. A very good partial response (VGPR) was included in the 
criteria and is indicated by ≥ 90% reduction in serum monoclonal protein with 
urine monoclonal protein of < 100 mg/24 hours (Rajkumar et al., 2011). A partial 
response (PR) requires ≥ 50% reduction in serum monoclonal protein and urine 
monoclonal protein of reduction of ≥ 90% or to < 200 mg/24 hours (Bladé et al., 
1998). A minimal response is indicated by a reduction in serum monoclonal 
protein levels of ≥ 25%, but <50%, and with urine monoclonal protein reduction 
by 50-489% which is still > 200 mg/24 hours. Patients not meeting any of the 
above criteria were designated as having a stable disease (SD). Progressive 
disease (PD) is defined as a > 25% increase from the best response which is 
also an absolute increase of ≥ 0.5 g/dL and/or increase in urine monoclonal 
protein increase by > 25% which is also an increase in ≥ 200 mg/24 hours.  
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Statistical Methods 
The Objective Response Rate (ORR) to treatment was determined using 
the response criteria previously reported (Bladé et al., 1998; Kraut et al., 1998; 
Rajkumar et al., 2011)and was defined as a response ≥ PR. With the intent-to-
treat, subjects who received at least one treatment on the protocol were included 
in the analysis. A 75% ORR was expected which is comparable to the results 
obtained from standard treatment and an ORR rate of 55% or less was 
considered inferior to the standard treatment. An exact binomial one-tailed test at 
a significance level of alpha equal to or less than 5% was used to evaluate 
whether the ORR is significantly greater than a test ORR of 55%. Our null 
hypothesis was that the response rate is 55% or less. If the ORR is greater than 
55% out of 50 subjects, the experimental regimen is considered non-inferior to 
the standard treatment. Alternatively, if the ORR is 66% or less, the study 
treatment is considered inferior in comparison to the standard treatment.  
Microsoft Office Excel 2010 was used for all descriptive statistics analysis 
which included mean, standard deviation, and percentage to summarize the 
patient demographics and baseline characteristics data. 
The time to next treatment was measured from the initiation of treatment 
to death or the beginning of another therapy at time of progression.  Progression 
free survival was measured from the time of bortezomib initiation to progression 
requiring alternative therapy. Duration of response was measured from the date 
of first response to either disease progression or relapse.  Overall survival was 
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defined as the time from initiation of bortezomib to confirmed death. The Kaplan-
Meier curve was used to calculate PFS, OS, TTNT, and the duration of response. 
Safety and toxicity were evaluated by analyzing the type, frequency and severity 
of adverse events.  
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RESULTS 
Demographics 
Fifty patients were enrolled into the study from 12 VA hospitals across the 
nation; of these, 49 were male and one was female. The ethnicities of the 
patients were as follows: 33 Caucasian, 13 African American, three 
Hispanic/Latino, and one was of another ethnicity. Of the 50 patients, 43 were 
evaluable for a response. The patients had a median Karnofsky Performance 
Score of 80, a median age of 71 (range, 50-89 years). Many of the subjects had 
a high-risk disease with 22 subjects who were International Staging System (ISS) 
stage II, 21 subjects who were ISS stage III. The median baseline CRP was 
10.61 ± 5.54 mg/L, and β-2 microglobulin was 5.80 ± 0.46 mg/L.  
Most of the patients (40%) had IgG kappa multiple myeloma and 24% had 
IgG Lambda myeloma. Seventy-four percent of the patients had lytic bone 
lesions. All the patients were taking at least four medications prior to enrollment 
in the study, with a median of 13 medications. Patient characteristics are 
summarized in Table 3. All the patients had significant co-morbidities that 
included 76% with cardiovascular problems, 34% with diabetes mellitus, and 
18% with pre-existing baseline neuropathy less than grade 2. Fifty-four percent of 
the patients had renal impairment, as defined by estimated Glomerular Filtration 
Rate (eGFR) < 60mL/min, prior to study initiation (Table 4). 
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Table 3. Demographics and baseline characteristics. Study patient population 
had advanced disease stages with 86% of patients who had ISS stage II/III. 
Disease Type N 
IgG, K 20 (40%) 
IgG, L 12 (24%) 
IgA, K 7 (14%) 
IgA, L 4 (8%) 
Lambda free light chain 4 (8%) 
Kappa free light chain 2 (4%) 
Biclonal, L 1 (2%) 
Number of Lytic Bone Lesions N 
More than 3 bones 22 (44%) 
1 -3 bones 15 (30%) 
None 13 (26%) 
International Staging System (ISS) N 
Stage I 6 (12%) 
Stage II 22 (44%) 
Stage III 21 (42%) 
β-2 Microglobulin 5.80 ± 0.46 mg/L 
C Reactive Protein 10.61 ± 5.54 mg/L 
Median number of medications 13 (Range: 4 – 24) 
Median Age 71 ± 1.46 years (Range: 50 – 89) 
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Table 4. Patient co-morbidities. Patients had significant co-morbidities at 
baseline which included 76% patients with cardiovascular, 54% with renal 
insufficiency, and 34% of patients with diabetes mellitus.  
Co-morbidities        N 
Cardiovascular 38 (76%) 
 Coronary Artery Disease 12 (24%) 
 Coronary Artery Bypass Graft 6 (12%) 
 Peripheral Vascular Disease 5 (10%) 
 Hypertension 26 (52%) 
Endocrine/Metabolic 38 (76%) 
 Diabetes Mellitus 17 (34%) 
 Hyperlipidemia 29 (58%) 
Pulmonary 18 (36%) 
 Asthma / COPD± 10 (20%) 
Urogenital 34 (68%) 
 Benign prostatic Hypertrophy 9 (18%) 
 Renal Insufficiency (eGFR < 60mL/min) 27 (54%) 
Neurological 14 (28%) 
Psychological 10 (20%) 
Musculoskeletal 32 (64%) 
Previous Cancer 9 (18%) 
± COPD: Chronic Obstructive Pulmonary Disease 
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Response and Survival 
Fifty subjects were enrolled into the study and of these, 43 were evaluable 
for response as data was unavailable for seven subjects for response evaluation. 
Five of the patients received less than one cycle, one died before response could 
be assessed, and the response for another one could not be confirmed with a 
second determination. Forty-four percent of evaluable patients achieved at least 
VGPR which included six who achieved nCR or CR, 79% had at least PR, and 
91% of evaluable patients attained at least MR. With the intent-to treat, the 
objective responses including all 50 subjects enrolled were 38% for at least 
VGPR, 68% with at least PR, and 78% with at least MR (Table 5). The median 
PFS was 9.6 months, TTNT was 11.8 months, and OS was 46.5 months based 
on the Kaplan-Meier curve calculations (Fig 3). Of the 27 subjects who initially 
had eGFR < 60mL/min at baseline, 52% had > 20% improvement in eGFR, of 
which, included seven patients who had > 60mL/min after treatment.  
The patients received a median of 5.8 cycles of treatment, and 23 of the 
subjects completed all 6 cycles. Seven of the patients had a reduction in their 
bortezomib dose to 1.3 mg/m2, four due to neuropathy. One patient’s dose was 
reduced to 1.0 mg/m2 due to a persistent grade 2 neuropathy with pain. 
Dexamethasone was reduced in 17 (34%) patients, mostly due to edema and 
hyperglycemia. Nineteen patients had disease progression after 6 cycles, one 
went on to receive an autologous stem cell transplant, and three had sustained 
response to treatment. Fifteen patients either had disease progression or stable 
  
29 
 
disease during the study, four patients withdrew from the study upon the family 
and of their own requests, two patients withdrew due to toxicity (grade 3 elevated 
creatinine, grade 4 diarrhea), and three patients were still being followed for 
response at the time of analysis.  
 
 
Table 5. Response rates of 43 evaluable subjects and all 50 subjects 
enrolled. 
Objective Response N 
% of 43 
(Evaluable) 
% of 50     
(Total 
enrolled) 
≥ VGPR 19 44% 38% 
≥ PR 34 79% 68% 
≥ MR 39 91% 78% 
CR 5 12% 10% 
nCR 1 2% 2% 
VGPR 13 30% 26% 
PR 15 35% 30% 
MR 5 12% 10% 
SD 4 9% 8% 
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Figure 3. Kaplan-Meier curves for progression-free survival (PFS), time-to-next treatment (TTNT), and 
overall survival (OS). (A) Median PFS = 9.6 months, (B) TTNT = 11.8 months, and (C) OS = 46.5 months.  
 
A 
C 
B 
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Adverse Events and Toxicities 
All fifty subjects enrolled in the study were included in the adverse events 
analysis. The most common non-hematologic adverse events were asthenia 
(53%) and constipation (42%), while the most common hematologic adverse 
events were lymphopenia (51%) and thrombocytopenia (47%). Hyperglycemia 
(62%) and edema (44%) were primarily attributed to the concurrent treatment of 
dexamethasone. The most common adverse events experienced by subjects are 
summarized in Table 6.  
Importantly, 27% (n=12) of patients developed bortezomib-induced 
peripheral neuropathy. Of the two patients with a baseline peripheral neuropathy 
of grade 1, one worsened to grade 2 with pain, and the other developed grade 3 
with pain (Table 7). Two other patients developed peripheral neuropathy of grade 
2 with pain, and eight patients developed grade 1 peripheral neuropathy while on 
the study.  
Out of the 50 subjects enrolled, six (12%) died during course of the study. 
The causes of deaths for all subjects were considered unrelated (atelectasis, 
tumor burden, congestive heart failure) or probably not related (acute cardiac 
event, cerebellar hemorrhage, unknown) to the bortezomib.  
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Table 6. Most common adverse events of all grades related to bortezomib and dexamethasone. 
Adverse Events Related to Bortezomib              Grade 1 & 2          Grade 3   Grade 4 Total 
Hematologic 
 Anemia 11 (22%) 2 (4%) -- 13 (26%) 
 Thrombocytopenia 20 (40%) 1 (2%) -- 21 (42%) 
 Lymphopenia 14 (28%) 9 (18%) -- 23 (46%) 
 Leukocytopenia 5 (10%) -- -- 5 (10%) 
 Neutropenia 3 (6%) -- -- 3 (6%) 
Non-hematologic 
 Diarrhea 15 (30%) 1 (2%) 1 (2%) 17 (34%) 
 Constipation 17 (34%) 2 (4%) -- 19 (38%) 
 Vomiting/Nausea 15 (30%) 1 (2%) -- 16 (32%) 
 Asthenia 20 (40%) 3 (6%) 1 (2%) 24 (48%) 
 Anorexia/ Dysphagia 9 (18%) -- -- 9 (18%) 
 Neuropathy 8 (16%) 3 (6%) -- 12 (24%) 
 Insomnia 6 (12%) -- -- 6 (12%) 
 Hypocalcemia 4 (8%) -- -- 4 (8%) 
 Hypoalbuminemia 2 (4%) -- -- 2 (4%) 
 Acute renal failure -- 2 (4%) -- 2 (4%) 
 Elevated creatinine 1 (2%) 1 (2%) -- 2 (4%) 
  
Adverse Events Related to 
Dexamethasone               Grade 1 & 2         Grade 3         Grade 4             Total 
Hyperglycemia 19 (42%) 7 (16%) 2 (4%) 28 (62%) 
Edema 20 (44%) -- -- 20 (44%) 
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Table 7. Treatment-emergent peripheral neuropathy. Ten patients developed 
neuropathy while on treatment. Of the six patients who had neuropathy at 
baseline, one patient worsened to grade 2 neuropathy with pain, and another had 
worsened to grade 3 with pain.   
 
 
 No Neuropathy 
at Baseline 
 Grade 1 
Neuropathy at 
Baseline 
Stable --  4 
Developed Grade 1 8  -- 
Developed Grade 2 with pain 2  1 
Developed Grade 3 with pain --  1 
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DISCUSSION 
Efficacy 
Efficacy and toxicity of bortezomib in newly-diagnosed and relapsed 
multiple myeloma patients has been extensively studied in a bi-weekly regimen 
at 1.3 mg/m2 (Jagannath et al., 2005; Richardson et al., 2003). In these studies, 
patients had significant treatment emergent peripheral neuropathy (31%), and 
12-25% of patients required dose reductions and 4-21% of patients discontinued 
bortezomib. In our study, we report a modified schedule evaluating the efficacy 
and safety of a higher once a week IV bortezomib dose in combination with 
dexamethasone on the day of and after bortezomib in patients eligible and 
ineligible for ASCT. We report that nCR/CR was observed in six patients (14%), 
at least VGPR in 19 (44%), PR in 15 (35%) and an ORR confirmed in 34 (79%) 
of the 43 evaluable patients. By intent-to-treat analysis, which included all 50 
patients who received at least one dose of bortezomib, 12% had nCR/CR, 38% 
with at least VGPR, PR in 35% and ORR in 68%. A Phase II multi-center 
Intergroupe Francophone du Myélome (IFM) study evaluated a twice a week IV 
bortezomib regimen of 1.3 mg/m2 with dexamethasone as an induction therapy 
before transplant (J. L. Harousseau et al., 2006). This study reported nCR/CR in 
21% of the patients, at least VGPR in 31%, PR in 35% and ORR in  66% of the 
patients (J. L. Harousseau et al., 2006). Phase III studies by the IFM group 
compared bortezomib plus dexamethasone (VD) versus bortezomib, thalidomide, 
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dexamethasone and VD versus vincristine, doxorubicin, and dexamethasone as 
induction for NDMM (J.-L. Harousseau et al., 2010; Moreau, Avet-Loiseau, et al., 
2011). For each of these studies, the VD arms had nCR/CR of 22% and 14.8%, 
at least VGPR of 36% and 37.7%, and ORR of 81% and 78.5% NDMM (J.-L. 
Harousseau et al., 2010; Moreau, Avet-Loiseau, et al., 2011). Our patient 
population had advanced ISS disease stages (Stage I: 12%; Stage II: 44%; 
Stage III: 42%), a high median β-2 microglobulin of 5.8 ± 0.46 mg/L, and a high 
median CRP 10.61 ± 5.54 mg/L at baseline. Despite these negative prognostic 
factors and the advanced age of our patients, reflective of the general population,  
the response rates in our study were similar to those reported in both studies with 
younger patients (median age = 57 years). This is important because a post-hoc 
analysis by Niesvizky et al. and Moreau et al. suggest that patients achieving 
optimal results during induction therapy with bortezomib plus dexamethasone 
correlates with better post-ASCT response and longer PFS without affecting 
stem cell collection (Moreau, Attal, et al., 2011; Niesvizky et al., 2008). A 
response of at least VGPR was observed in 44% of patients, suggesting that this 
once a week regimen may also be beneficial to transplant-eligible patients and 
does not preclude them from transplant. Although most of our patients were older 
and transplant ineligible due to various reasons, the modified regimen proposed 
in the present study may also be beneficial as induction therapy for transplant-
eligible patients. 
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The present study also confirms that weekly bortezomib regimen is well 
tolerated by patients with renal impairment and that renal impairment can 
improve and even reverse renal insufficiency in some cases. Renal insufficiency 
is a common complication, affecting 20-40% of all NDMM patients (Eleutherakis-
Papaiakovou et al., 2007; Kyle et al., 2003) and this can limit treatment options 
involving other novel agents, such as lenalidomide, which are primarily excreted 
through the kidneys (“Revlimid (Lenalidomide) Drug Information,” n.d.). 
Alternatively, bortezomib is primarily metabolized in the liver and is safe to use in 
patients with significant renal impairment. Of the 27 (54%) subjects who had an 
eGFR < 60mL/min, seven (26%) had reversal of renal insufficiency in our study 
which was comparable to the 38.9% observed in another study involving twice a 
week bortezomib and dexamethasone (Li et al., 2009). 
 
Safety and Toxicity 
The higher dosed once weekly regimen was well-tolerated with lower 
incidences of treatment-emergent toxicities than the standard twice a week 
regimen. We observed grade 3 peripheral neuropathy with pain in only one 
patient (2%), and only 12 patients (24%) experienced treatment-related 
peripheral neuropathy; none of the patients discontinued treatment due to 
peripheral neuropathy. Additionally, no patients withdrew due to peripheral 
neuropathy. These results were lower than the twice a week administration and 
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more comparable to the once a week administration of bortezomib previously 
reported in the GIMEMA Phase III trial which observed grade 3/4 peripheral 
neuropathy of 28% versus 8%, and treatment-emergent neuropathy in 46% 
versus 27%, respectively (Bringhen et al., 2010).  Furthermore, an analysis of the 
Phase II APEX (Assessment of Proteasome Inhibition for Extending Remission) 
study which used a twice weekly bortezomib as a single-agent treatment in 
relapsed multiple myeloma showed that 64% of patients who experienced ≥ 
grade 2 treatment-emergent peripheral neuropathy had improved or resolved to 
baseline with a median time to improvement/resolution of 110 days after 
discontinuation of therapy (Richardson, Sonneveld, et al., 2009). This 
improvement in peripheral neuropathy included 68% of patients who had 
bortezomib dose modifications (Richardson, Sonneveld, et al., 2009). Similar 
reversal of neuropathy were also observed in another study for untreated multiple 
myeloma patients, in which 64% patients experienced treatment-emergent 
neuropathy and 85% of those patients had a resolution of neuropathy with a 
median time to resolution of 98 days (Richardson, Xie, et al., 2009).These 
studies corroborate that a carefully modified dose of bortezomib can improve 
neurotoxicity and tolerability without compromising efficacy, even for patients 
who may otherwise have discontinued treatment due to unacceptable 
neurotoxicity. Thus, a higher once a week dose of bortezomib regimen in 
combination with dexamethasone is safe and well-tolerated, without 
compromising efficacy due to significant dose reductions or discontinuation. 
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In conclusion, this prospective study demonstrates that weekly 
intravenous bolus bortezomib of 1.6 mg/m2 with dexamethasone on the day of 
and after bortezomib is efficacious and is well tolerated especially with lower 
drug-related neurotoxicity compared to the twice a week schedule for newly 
diagnosed elderly patients with multiple co-morbidities. Despite the less frequent 
dosing schedule, efficacy was not compromised and it can be used as an 
induction therapy for pre-ASCT patients, transplant ineligible patients, as well as 
patients on dialysis or have significant renal impairment. 
 
Future Directions 
Since the FDA’s approval of subcutaneous (SC) administration in 2012, a 
multi-national Phase III study comparing twice a week SC bortezomib with twice 
a week IV bortezomib injection in relapsed multiple myeloma patients has 
demonstrated that SC has similar efficacy with an ORR of 42% in both arms 
(Moreau, Pylypenko, et al., 2011). An updated survival analysis of the Phase III 
MMY-3021 study showed that both SC and IV administration of bortezomib had 
comparable median time to progression (9.7 months versus 9.6 months), PFS 
(9.3 months versus 8.4 months), and 1-year OS (76.4% versus 78%), 
respectively (Arnulf et al., 2012). Peripheral neuropathy of all grades were lower 
in the SC arm (35%) than in the IV arm (49%) and grade ≥ 3 peripheral 
neuropathy were 5% and 15% for each arm, respectively (Moreau, Pylypenko, et 
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al., 2011). Although less, peripheral neuropathy was still a significant adverse 
issue related to bortezomib. In addition, elderly patients have several factors 
including frailty, difficult venous access, and mobility issues which can all 
contribute to dose interruptions and treatment adherence. A retrospective study 
evaluating the efficiency of chemotherapy administration and cross-sectional 
patient survey showed that more patients preferred a SC administration of 
bortezomib citing convenience and shorter duration of the time spent receiving 
the treatment, as well as a shorter overall time per visit (Barbee et al., 2013). 
Reduction in the treatment duration was quantified as approximately 54 minutes 
(38% reduction) and the overall visit time was reduced by 46 minutes (27% 
reduction) for people who received SC bortezomib (Barbee et al., 2013). 
However, it is important to note that despite improvement in convenience, close 
monitoring of adverse events and follow-up of patients may be a potential 
problem for SC administration. Mobility and transportation is also a significant 
issue for many veterans who are homeless or live far from a VA hospital with 
facilities for chemotherapy treatments. A prospective study investigating the 
safety and efficacy of once a week SC administration of bortezomib with 
dexamethasone in NDMM patients may further benefit the elderly population with 
several co-morbidities translating to reduced neurotoxicity and less dose 
interruptions without compromising efficacy. 
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APPENDIX 1: Participating Veterans Affairs Hospitals 
 
VA Boston Healthcare System, Boston, MA (Coordinating site). 
Principal Investigator: Nikhil C. Munshi, M.D. 
 
VA Connecticut Healthcare System, West Haven, CT. 
Subsite-Principal Investigator: Michal Rose, M.D.; 
      Manuel F. Rosado, M.D. 
 
Kansas City VA Medical Center, Kansas City, MO. 
 Subsite-Principal Investigator: Suman Kambhampati, M.D. 
 
West Los Angeles Medical Center, Los Angeles, CA. 
Subsite-Principal Investigator: Alan Lichtenstein, M.D. 
 
VA Pittsburgh Healthcare System Home, Pittsburgh, PA. 
Subsite-Principal Investigator: David G. Roodman, M.D.;  
      Vida Passero, M.D.; Andrew Liman, M.D.  
 
James A. Haley Veterans Hospital, Tampa, FL. 
Subsite-Principal Investigator: Hussein Saba, M.D.; Terrence Grady, D.O. 
 
San Francisco VA Medical Center, San Francisco, CA. 
Subsite-Principal Investigator: Caroline Behler, M.D. 
 
Central Arkansas Veterans Healthcare System John L. McClellan Memorial 
Veterans Hospital, Little Rock, AR. 
Subsite-Principal Investigator: Paulette Mehta, M.D. 
 
VA Eastern Colorado Health Care System, Denver, CO. 
Subsite-Principal Investigator: Catherine Klein, M.D. 
 
Atlanta VA Medical Center, Decatur, GA. 
Subsite-Principal Investigator: Abid Mohuiddin, M.D.; Maria Ribeiro, M.D. 
 
Jesse Brown VA Medical Center, Chicago, IL. 
Subsite-Principal Investigator: Charles L. Bennett, M.D. 
 
Michael E. DeBakey VA Medical Center, Houston, TX. 
Subsite-Principal Investigator: Sarvari Yellapragada, M.D.;  
      Teresa Hayes, M.D.  
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APPENDIX 2: Eligibility Criteria 
Inclusion Criteria: 
1. Initial diagnosis of multiple myeloma based on standard criteria. 
 
2. Measurable disease, defined as a monoclonal immunoglobulin spike on 
serum  electrophoresis of > 1 Gm/dL and/or urine monoclonal immunoglobulin 
spike of  > 200 mg/24 hours. 
 
3. Non–secretors must have measurable protein by Freelite or measurable 
disease such as plasmacytoma to be eligible. 
 
4. Patient must not have been previously treated with chemotherapy.  Prior 
treatment of hypercalcemia with corticosteriods, or bisphosphonates does not 
disqualify the patient. 
 
5. a.   Patient must be ineligible for autologous stem cell transplant due to one or 
more of the following reasons: 
• Age > 65. 
• Impaired renal function (creatinine ≥ 2.0 mg/dL). 
• Impaired pulmonary function (DLCO ≤ 50%). 
• Poor performance status (KPS ≤ 80). 
• Other prohibitive comorbid disorder. 
 
b. Patients ≥60 who decline autologous stem cell transplant are eligible for 
this study.  
c. Patients who are eligible but wish to postpone autologous stem cell 
transplant are eligible for this study. 
 
6. Karnofsky performance score > 50. 
 
7. Patients treated with local radiotherapy with or without a brief exposure to 
steroids are eligible. Patients who require concurrent radiotherapy should 
have entry to the protocol deferred until the radiotherapy (RT) is completed, 
followed by a four week wash out period. Spot RT to ≤3 vertebrae acceptable 
prior to entry. 
 
8. Meets the following pretreatment laboratory criteria at Baseline (Within 14 
days prior to study drug administration): 
a. Platelet count > 50 x 109/L or, if the bone marrow is extensively 
infiltrated, > 30 x 109/L. 
b. Hemoglobin > 8.0 G/dL. 
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c. Absolute neutrophil count  > 1.0 x 109/L  or, if the bone marrow is 
extensively infiltrated, > 0.5 x 109/L. 
 
9. Meets the following pretreatment laboratory criteria for liver function tests at 
the screening visit conducted within 14 days of registration: 
a. AST (SGOT): < 3 times the upper limit of institutional laboratory normal. 
b. ALT (SGPT): < 3 times the upper limit of institutional laboratory normal. 
c. Total bilirubin: < 2 times the upper limit of institutional laboratory 
normal, unless clearly related to the disease. 
 
10. Women with child-bearing potential should be practicing an adequate form of 
contraception, as judged by the investigator (i.e. birth control pills, double 
barrier method, abstinence, etc.) or be surgically sterile or 12 months post-
menopausal. Male subject agrees to use an acceptable method for 
contraception for the duration of the study.                                                                       
 
11. Age 18 years or older. 
 
12. Has given voluntary written informed consent, prior to any study-related 
procedure not part of normal medical care, with the understanding that the 
patient may withdraw consent at any time without prejudice to future medical 
care. 
 
Exclusion Criteria 
1. POEMS syndrome (plasma cell dyscrasia with polyneuropathy, 
organomegaly, 
 endocrinopathy, monoclonal protein and skin changes) 
 
2. Plasma cell leukemia. 
          
3. Impaired kidney function requiring dialysis, patients on hemodialysis are 
excluded. 
 
4. Receiving steroids > the equivalent of 10 mg prednisone daily for other 
medical conditions, e.g., asthma, systemic lupus erythematosis, rheumatoid 
arthritis. 
 
5. Infection not controlled by antibiotics. 
 
6. HIV infection.  Patients should provide consent for HIV testing according to 
the institution’s standard practice. 
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7. Known active hepatitis B or C. 
 
8. Myocardial infarction within 6 months prior to enrollment or has New York 
Heart Association (NYHA) Class III or IV heart failure uncontrolled angina, 
severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence 
of acute ischemia or active conduction system abnormalities. 
  
9. Second malignancy requiring concurrent treatment. 
 
10. Other serious medical or psychiatric illness that could potentially interfere with 
the completion of treatment according to this protocol. 
      
11. Positive pregnancy test in women of childbearing potential. 
 
12. Patient has hypersensitivity to boron or mannitol. 
 
13. Patient has ≥ Grade 2 peripheral neuropathy within 14 days before enrollment. 
 
14. Patient has received other investigational drugs with 14 days before 
enrollment 
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APPENDIX 3: Bortezomib Dose Reduction Guideline for Neuropathy 
Severity of Peripheral Neuropathy Modification 
Grade 1 (paresthesias and/or loss 
of reflexes without pain or loss of 
function) 
Monitor closely. No action 
Grade 1 with pain or Grade 2 
(interfering with function but not 
with activities of daily ling) 
Reduce by one dose level (depending on 
current dose): 
• 1.6 mg/m2 per dose → 1.3 mg/m2 per 
dose 
• 1.3 mg/m-2 per dose → 1.0 mg/m2 per 
dose 
• 1.0 mg/m2 per dose → 0.7 mg/m2 per 
dose 
Grade 2 with pain or Grade 3 
(interfering with activities of daily 
living) 
Hold bortezomib until toxicity resolves (may 
hold up to 2 weeks until toxicity improves to 
grade 1 or better) 
 
When toxicity resolves, resume protocol 
with two dose level reduction (depending 
on current dose): 
• 1.6 mg/m2 per dose → 1.0 mg/m2 per 
dose 
• 1.3 mg/m-2 per dose → 0.7 mg/m2 per 
dose 
Grade 4 (Permanent sensory loss 
that interferes with function) 
Discontinue bortezomib 
 Grading is based on the National Cancer Institute CTCAE v 3.0 (“Microsoft Word 
- CTCAEv3_PubDate_2006-08-09.doc - ctcaev3.pdf,” n.d.) 
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APPENDIX 4: Schedule of Assessments 
 
 
Screening 
Day 
1 
Day 
8 
Day 
15 
Day 
22 
End of 
Study 
Follow-
up 
Informed Consent X       
Medical History X       
Physical Exam – symptom directed X Xa    X X 
Karnofsky Performance Score X Xa X X X X X 
Vitals X Xa X X X X X 
Height, Weight X Xa      
Skeletal Survey X     Xb  
Bone Marrow Biopsy X     Xb  
EKG/Chest X-ray X       
HIV test X       
Multiple Myeloma Assessments 
• Serum immunofixation/Serum protein 
electrophoresis with quantitated m-protein X X
a
    X X 
• Quantitative Immunoglobulins X Xa    X X 
• Serum Free Light Chain X Xa    X X 
• 24hr Urine total protein and urine protein 
electrophoresis X
 Xa,c    Xc Xc 
• β2-microglobulin X     X  
• C-reactive protein X     X  
Blood Chemistry 
• Electrolytes X Xa X X X X X 
• Calcium, glucose, BUN, creatinine X Xa X X X X X 
• Albumin X Xa     X 
Liver Function Test X Xa    X X 
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• AST (SGOT)        
• ALT (SGPT)        
• Total Bilirubin        
• Alkaline Phosphatase        
CBC, differential and platelet count X Xa X X X X X 
Serum Pregnancy Test X Xa    X  
Bortezomib Dosing  X X X X   
Dexamethasone Dosing  Xd Xd Xd Xd   
Concomitant medication query X Xa      
Assessment of Response  Xe      
Adverse Events query  X X X X X  
    
a. Day 1 of each cycle except for cycle 1 (if not performed at screening). 
b. Performed at End of Study only to confirm complete response or if clinically indicated. 
c. Performed only if protein in urine was present at screening. 
d. Dexamethasone is administered on the days 1 and 2, 8 and 9, 15 and 16, 22 and 23 (day of and day after bortezomib 
administration). 
e. Repeat at end of cycle 2, 4, 6. 
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